Ticker: LLY

Eli Lilly

Pharma Healthcare Drug Manufacturers - General

Price 1203.14

Reco Buy Potential 83 Risk 28 Updated 2026-07-27

Official website

Forecast impact

positive

Target +15.8% target fill 86.4%

Reaction D5 +0.63% · D10 +2.64% fresh confirmed · market trust

Impact Potential +6 · Risk -3 valid until 2026-08-13

Track in portfolio

Price chart

AI recommendation Analyst forecast Calendar event Positive signal Negative signal Neutral / update Hold / informational B My buy S My sell

Description

Company and Business Model

Eli Lilly is a global healthcare company that focuses on the discovery, development, and commercialization of pharmaceuticals. Its core products include treatments for diabetes, oncology, immunology, and neurodegenerative diseases. Major business segments consist of diabetes care, oncology, and neuroscience, with significant revenue generated from insulin products and cancer therapies. The company is recognized for its innovative drug pipeline and strong market presence in the healthcare sector.

Investment Profile

Eli Lilly's stock is positioned as a balanced investment, appealing to investors seeking moderate growth and some income through dividends. The company demonstrates stable revenue growth and a consistent dividend yield, making it suitable for those looking for a mix of capital appreciation and income. Its established market presence and ongoing product development contribute to a favorable risk-return profile.

Category: Pharma Sector: Healthcare Industry: Drug Manufacturers - General Investment style: Growth Horizon: Long-term Company type: Blue Chip Company type: Market Leader Experience: Basic

Fundamental metrics (experimental) Updated: 2026-07-24

EPS (TTM) — earnings per share for the last 12 months, $: 28.20
Revenue QoQ — quarter-over-quarter revenue growth: 2.6%
EPS surprise: 22.7%
20d volatility: 1.6%
Dividend yield: 0.7%
last ex-date: 2026-08-14

AI recommendation changes

Date	Before	After	Reason
2026-05-18	Hold	Buy	Strong fundamentals and positive short-term momentum.
2026-05-10	Buy	Hold	Weak momentum and high risk; mixed analyst signals.
2026-05-08	—	Buy	Solid fundamentals but mixed momentum signals.
2026-05-08	Buy	Buy	Компания показывает стабильный рост выручки и положительные сюрпризы по EPS, однако недавние колебания цен и негативная динамика на более длительных сроках вызывают осторожность.
2026-04-29	Hold	Buy	Компания Eli Lilly демонстрирует стабильный рост выручки и положительный сюрприз по прибыли, однако недавние колебания цен акций и снижение на более длительных горизонтах вызывают опасения. Рекомендуется удерживать акции
2026-04-17	Buy	Hold	Компания Eli Lilly демонстрирует стабильный рост выручки и положительный сюрприз по EPS, однако недавние колебания цен акций и снижение на коротких временных интервалах могут указывать на повышенные риски.
2026-04-09	Hold	Buy	Компания Eli Lilly демонстрирует стабильный рост выручки и положительные результаты по EPS, что указывает на сильные финансовые показатели. Несмотря на недавние колебания цен, долгосрочные тренды и позитивные прогнозы де
2026-03-22	Buy	Hold	Компания Eli Lilly демонстрирует сильный рост выручки и положительный сюрприз по прибыли, однако недавнее снижение цен акций и высокая волатильность могут указывать на риски в краткосрочной перспективе.
2026-02-06	Hold	Buy	Компания Eli Lilly демонстрирует сильный рост за последние 120 дней, однако недавнее падение на 7.79% может указывать на краткосрочные риски. Рекомендуется удерживать акции до более ясной картины.
2026-01-29	Buy	Hold	Компания Eli Lilly демонстрирует сильный рост за последние 60 и 120 дней, однако недавние колебания цен указывают на возможную волатильность. Рекомендуется удерживать акции до более ясных сигналов о дальнейшем движении.

Analyst forecasts

Date	Analyst	Action	Target	Price Then
2026-07-14	Bernstein	Target Raised	— → 1385	1185.08
2026-07-13	UBS	Target Raised	1250 → 1425	1189.91003
2026-07-13	Guggenheim	Target Raised	— → 1273	1188.58
2026-07-09	UBS	Target Raised	1281 → 1370	1222.125
2026-07-08	Truist Financial	Target Raised	— → 1370	1227.07
2026-07-08	RBC Capital	Target Raised	1250 → 1500	1229.21997
2026-07-08	Morgan Stanley	Target Raised	1344 → 1347	1235.56
2026-07-06	Cantor Fitzgerald	Target Raised	— → 1350	1210.5
2026-06-25	Leerink Partners	Target Raised	1119 → 1232	1117.26
2026-06-22	Berenberg Bank	Target Raised	1050 → 1135	1111.67
2026-06-09	Jefferies	Target Raised	1330 → 1350	1143.35
2026-05-26	HSBC	Target Raised	— → 1251	1065
2026-05-26	Leerink Partners	Update	— → 1119	1065
2026-05-21	Wolfe Research	Target Raised	1325 → 1350	1037.82007
2026-05-05	Barclays	Target Raised	1350 → 1400	967.93
2026-05-01	Morgan Stanley	Target Raised	1327 → 1344	961.555
2026-05-01	Cantor Fitzgerald	Target Raised	1205 → 1230	970.675
2026-04-10	Morgan Stanley	Target Raised	1313 → 1327	939.31
2026-03-13	Jefferies	Update	— → 1300	1000.78003
2026-03-06	Deutsche Bank	Update	— → 1285	990.31
2026-03-05	Morgan Stanley	Update	— → 1313	972.5

News Page 1 of 4

Stocks Decline Amid Geopolitical Tensions and Mixed Earnings Reports

07/25/2026, 01:31 PM economy review ai tech Alphabet Intel Johnson & Johnson Eli Lilly

The stock market faced significant challenges this week, primarily driven by rising oil prices due to geopolitical tensions and mixed earnings reports from major tech companies, which have heightened concerns about inflation and interest rates.

Stocks to Watch: Lockheed Martin Surges on Earnings Beat, Tesla Falls After Earnings Miss

07/23/2026, 05:36 AM business review Comcast Alphabet IBM Tesla Lockheed Martin Texas Instruments Eli Lilly

Tesla's shares fell nearly 6% following a disappointing earnings report, while Lockheed Martin's stock rose 6% after exceeding profit expectations. Alphabet also saw a decline as it raised its capital expenditure forecast significantly to enhance its AI capabilities.

Eli Lilly Plans to File for Approval of Next-Generation Obesity Drug Retatrutide in 2027 Following Successful Trials

07/23/2026, 04:37 AM business announcement healthcare Eli Lilly

Eli Lilly plans to seek approval for its next-generation obesity drug, retatrutide, in early 2027 after successful late-stage trials, highlighting its potential to capture a significant share of the growing obesity and diabetes treatment market.

Trump Announces Tariff Plan on Generic Drugs to Encourage U.S. Production Starting in 2028

07/21/2026, 06:36 PM economy announcement Novo Nordisk Pfizer Eli Lilly

President Trump's announcement of zero tariffs on imported generic drugs for two years, followed by steep increases, aims to incentivize domestic production and could significantly impact the pharmaceutical sector, particularly for companies reliant on foreign manufacturing.

Novo Nordisk Files Lawsuit Against Eli Lilly Over Misleading Advertising for GLP-1 Drugs

07/21/2026, 05:37 AM business announcement pharma Novo Nordisk Eli Lilly

Novo Nordisk has filed a lawsuit against Eli Lilly, claiming that Lilly's advertising misrepresents the efficacy of its diabetes and obesity drugs compared to Novo's products. This legal action highlights the competitive tensions in the GLP-1 drug market, particularly as Novo seeks to regain market share with its new high-dose Wegovy injection.

Eli Lilly to Acquire AtaiBeckley for Up to $3.8 Billion, Signaling Big Pharma’s Shift Towards Psychedelic Drugs for Mental Health Treatment

07/19/2026, 08:31 AM business announcement healthcare Eli Lilly

Eli Lilly's acquisition of AtaiBeckley for up to $3.8 billion highlights the pharmaceutical industry's growing interest in psychedelic drugs as viable treatments for mental health disorders, particularly treatment-resistant depression. This move signals a potential shift in the market, as positive clinical trial results and regulatory support pave the way for broader acceptance and commercialization of these therapies.

Stocks Making Significant Moves Premarket: UnitedHealth, TSMC, GE Aerospace, J.B. Hunt, and More

07/16/2026, 05:36 AM business review General Electric UnitedHealth Taiwan Semiconductor Manufacturing Company Atai Life Sciences Rocket Companies J.B. Hunt Transport Services AeroVironment Eli Lilly

Premarket trading saw significant movements, particularly for UnitedHealth and AtaiBeckley, which reported strong earnings and acquisition news, respectively, impacting investor sentiment and stock valuations.

Eli Lilly Acquires Psychedelic Drugmaker AtaiBeckley for $2.8 Billion to Enhance Mental Health Treatment Portfolio

07/16/2026, 04:36 AM business announcement Atai Life Sciences Eli Lilly

Eli Lilly's acquisition of AtaiBeckley for $2.8 billion highlights the growing interest in psychedelic drugs as potential treatments for mental health issues, particularly treatment-resistant depression.

Employers Remain Reluctant to Expand Coverage for GLP-1 Obesity Drugs Despite Rising Demand

07/08/2026, 06:36 AM business review healthcare Novo Nordisk Eli Lilly

Despite the introduction of new GLP-1 drugs and Medicare coverage for obesity, employer coverage for these medications remains stagnant, primarily due to high costs. This trend could impact the market for GLP-1 drugs and the overall healthcare landscape as employers seek alternative ways to support employee health.

Analysts UBS recommend adding low volatility stocks to portfolios, highlighting Yum Brands (YUM), Lockheed Martin (LMT), and McDonald’s (MCD)

07/07/2026, 12:35 PM investing recommendation Analysts: analysts, UBS consumer industrials Stryker Keurig Dr Pepper Medtronic Charles Schwab McDonald's Yum Brands Lockheed Martin Eli Lilly

UBS recommends that investors consider adding low volatility stocks to their portfolios following a strong first half of 2026 for the S&P 500, which rose 9.6%. This strategy aims to mitigate potential market turbulence as investors navigate ongoing economic uncertainties.